Share Price and Basic Stock Data
Last Updated: November 10, 2025, 11:59 pm
| PEG Ratio | 3.83 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Elantas Beck India Ltd operates within the chemicals industry, focusing on organic chemicals. As of October 2023, the company’s market capitalization stood at ₹7,701 Cr, with its stock price at ₹9,714. The company’s sales have shown a consistent upward trend, with reported sales of ₹645 Cr in December 2022, rising to ₹680 Cr in December 2023, and projected at ₹749 Cr for December 2024. The trailing twelve months (TTM) sales reached ₹797 Cr, indicating a robust growth trajectory. Quarterly sales figures also reflect this trend, with the latest quarter ending June 2025 showing sales of ₹210 Cr. This steady growth in revenue underscores the company’s strong market position and demand for its products. Despite fluctuations in quarterly sales, such as a decline to ₹163 Cr in September 2023, the overall trend remains positive, showcasing resilience in a competitive environment.
Profitability and Efficiency Metrics
Elantas Beck India Ltd’s profitability metrics present a favorable picture, with a reported net profit of ₹133 Cr and a net profit margin of 18.64% for December 2024. The operating profit margin (OPM) stood at 19% as of the latest reporting, indicating effective cost management and operational efficiency. The company reported an impressive return on equity (ROE) of 17.4% and return on capital employed (ROCE) of 23.0%. The interest coverage ratio (ICR) is exceptionally high at 302.41x, reflecting the absence of debt, which is a significant strength. However, fluctuations in quarterly operating profit, such as a dip to ₹33 Cr in September 2024, suggest potential challenges in maintaining consistent profitability across periods. Overall, the company’s ability to generate profit while managing expenses effectively positions it favorably relative to industry standards.
Balance Sheet Strength and Financial Ratios
Elantas Beck India Ltd’s balance sheet reveals a strong financial position, characterized by zero borrowings and reserves amounting to ₹925 Cr as of June 2025. The company’s current ratio is robust at 6.26, indicating excellent short-term liquidity. The price-to-book value (P/BV) ratio is reported at 11.68x, suggesting that the market values the company’s equity significantly higher than its book value, which stood at ₹1,093.78 per share. The company’s total assets increased to ₹1,096 Cr in June 2025, reflecting growth in fixed assets and investments. The efficiency ratios, including a cash conversion cycle of 64 days, indicate effective management of working capital. However, the high P/BV ratio compared to typical sector ranges may suggest overvaluation risks, necessitating careful investor scrutiny. This financial robustness, combined with strong liquidity, provides a solid foundation for future growth.
Shareholding Pattern and Investor Confidence
The shareholding structure of Elantas Beck India Ltd indicates strong promoter confidence, with promoters holding 75% of the total shares. Institutional investors, including domestic institutional investors (DIIs), hold 12.17%, while foreign institutional investors (FIIs) represent a minimal 0.04%. The gradual increase in the number of shareholders from 7,145 in December 2022 to 8,892 in June 2025 reflects growing investor interest in the company. Despite the overall stability in shareholding, the decline in FII participation from 0.82% in December 2022 to 0.04% in June 2025 may raise concerns regarding international investor confidence. The consistent dividend payout of ₹7.50 per share in December 2024, alongside a low dividend payout ratio of 2.84%, demonstrates the company’s commitment to returning value to shareholders while retaining earnings for reinvestment. This strong shareholding pattern underlines the company’s stability and investor trust in its future prospects.
Outlook, Risks, and Final Insight
Looking ahead, Elantas Beck India Ltd appears well-positioned for growth, bolstered by its strong financial metrics and a solid market presence. However, potential risks include fluctuations in quarterly performance, as evidenced by the varying sales figures, and the high P/BV ratio that could indicate overvaluation. Additionally, the declining trend in FII investment may signal concerns regarding external market perceptions. To mitigate these risks, the company must focus on maintaining operational efficiency and consistent revenue growth. The absence of debt provides a cushion against economic downturns, allowing for strategic investments. Overall, while the company has a robust foundation and promising growth potential, it must navigate market challenges effectively to sustain its upward trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Elantas Beck India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 116 Cr. | 325 | 456/255 | 120 | 390 | 0.03 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,797 Cr. | 9,835 | 14,250/8,150 | 56.4 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 37.0 Cr. | 123 | 329/114 | 14.9 | 24.9 | 0.81 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 35.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 248 Cr. | 310 | 385/163 | 19.2 | 94.6 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,342.00 Cr | 1,643.15 | 408.86 | 330.79 | 0.37% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 171 | 153 | 165 | 169 | 173 | 163 | 174 | 177 | 191 | 184 | 197 | 206 | 210 |
| Expenses | 141 | 129 | 136 | 134 | 138 | 126 | 138 | 139 | 153 | 150 | 162 | 166 | 170 |
| Operating Profit | 30 | 24 | 29 | 36 | 35 | 37 | 36 | 38 | 39 | 33 | 35 | 40 | 40 |
| OPM % | 17% | 16% | 17% | 21% | 20% | 23% | 20% | 21% | 20% | 18% | 18% | 20% | 19% |
| Other Income | 1 | 14 | 10 | 8 | 15 | 12 | 17 | 15 | 17 | 12 | 10 | 9 | 18 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 |
| Profit before tax | 28 | 35 | 35 | 40 | 47 | 47 | 49 | 49 | 52 | 42 | 40 | 44 | 53 |
| Tax % | 26% | 22% | 25% | 26% | 25% | 25% | 25% | 25% | 20% | 25% | 26% | 26% | 26% |
| Net Profit | 21 | 27 | 26 | 30 | 35 | 35 | 37 | 37 | 42 | 31 | 30 | 33 | 39 |
| EPS in Rs | 25.95 | 34.07 | 33.40 | 37.91 | 44.68 | 43.93 | 46.67 | 46.56 | 52.79 | 39.19 | 37.51 | 41.46 | 49.56 |
Last Updated: August 19, 2025, 7:30 pm
Below is a detailed analysis of the quarterly data for Elantas Beck India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 206.00 Cr. (Mar 2025) to 210.00 Cr., marking an increase of 4.00 Cr..
- For Expenses, as of Jun 2025, the value is 170.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 166.00 Cr. (Mar 2025) to 170.00 Cr., marking an increase of 4.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 40.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 40.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Mar 2025) to 19.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00%.
- For Net Profit, as of Jun 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 49.56. The value appears strong and on an upward trend. It has increased from 41.46 (Mar 2025) to 49.56, marking an increase of 8.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:26 am
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 304 | 341 | 344 | 365 | 383 | 409 | 394 | 383 | 522 | 645 | 680 | 749 | 797 |
| Expenses | 265 | 299 | 282 | 287 | 304 | 344 | 340 | 313 | 444 | 535 | 537 | 604 | 648 |
| Operating Profit | 39 | 42 | 62 | 79 | 78 | 65 | 54 | 70 | 78 | 110 | 143 | 144 | 148 |
| OPM % | 13% | 12% | 18% | 22% | 20% | 16% | 14% | 18% | 15% | 17% | 21% | 19% | 19% |
| Other Income | 11 | 8 | 6 | 8 | 9 | 31 | 18 | 22 | 25 | 32 | 53 | 55 | 50 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 5 | 5 | 6 | 5 | 6 | 7 | 7 | 12 | 12 | 12 | 12 | 15 | 19 |
| Profit before tax | 45 | 45 | 62 | 81 | 81 | 89 | 64 | 80 | 91 | 129 | 184 | 183 | 179 |
| Tax % | 29% | 30% | 32% | 33% | 32% | 26% | 22% | 23% | 27% | 24% | 25% | 24% | |
| Net Profit | 32 | 32 | 42 | 54 | 55 | 66 | 50 | 62 | 67 | 98 | 137 | 140 | 133 |
| EPS in Rs | 40.05 | 39.87 | 52.68 | 68.73 | 69.48 | 82.99 | 62.51 | 77.90 | 84.36 | 123.34 | 173.19 | 176.04 | 167.72 |
| Dividend Payout % | 137% | 11% | 9% | 7% | 6% | 5% | 8% | 6% | 6% | 4% | 3% | 4% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 14% |
| 3 Years: | 13% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 23% |
| 3 Years: | 33% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 34% |
| 3 Years: | 34% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 17% |
| 3 Years: | 18% |
| Last Year: | 17% |
Last Updated: September 5, 2025, 3:21 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 53 | 59 | 53 | 70 | 75 | 57 | 67 | 61 | 58 | 55 | 62 |
| Inventory Days | 81 | 84 | 85 | 100 | 75 | 74 | 77 | 89 | 95 | 73 | 68 | 78 |
| Days Payable | 44 | 55 | 64 | 73 | 73 | 71 | 56 | 103 | 86 | 67 | 81 | 76 |
| Cash Conversion Cycle | 93 | 82 | 80 | 80 | 71 | 78 | 77 | 54 | 70 | 64 | 41 | 64 |
| Working Capital Days | 9 | 58 | 55 | 55 | 62 | 69 | 59 | 46 | 57 | 48 | 33 | 56 |
| ROCE % | 34% | 35% | 40% | 41% | 33% | 23% | 18% | 19% | 17% | 22% | 28% | 23% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 614,625 | 1.39 | 716.94 | 614,625 | 2025-04-22 17:25:12 | 0% |
| Tata Small Cap Fund | 215,767 | 3.55 | 251.68 | 215,767 | 2025-04-22 17:25:12 | 0% |
| Tata Large & Mid Cap Fund - Regular Plan | 102,551 | 1.64 | 119.62 | 102,551 | 2025-04-22 15:56:50 | 0% |
| Tata Large & Mid Cap Fund - Regular Plan | 102,551 | 1.64 | 119.62 | 102,551 | 2025-04-22 17:25:12 | 0% |
| Union Small Cap Fund | 7,314 | 0.6 | 8.53 | 7,314 | 2025-04-22 15:56:50 | 0% |
| Union Retirement Fund | 1,300 | 1.2 | 1.52 | 1,300 | 2025-04-22 15:56:50 | 0% |
| Union Childrens Fund | 441 | 1.1 | 0.51 | 441 | 2025-04-22 15:56:50 | 0% |
| Union Equity Savings Fund | 321 | 0.3 | 0.37 | 321 | 2025-04-22 15:56:50 | 0% |
Key Financial Ratios
| Month | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 176.05 | 173.18 | 123.34 | 84.36 | 77.91 |
| Diluted EPS (Rs.) | 176.05 | 173.18 | 123.34 | 84.36 | 77.91 |
| Cash EPS (Rs.) | 195.01 | 188.19 | 138.97 | 99.64 | 92.67 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1093.78 | 923.34 | 755.07 | 636.59 | 557.02 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1093.78 | 923.34 | 755.07 | 636.59 | 557.02 |
| Dividend / Share (Rs.) | 7.50 | 5.00 | 5.00 | 5.00 | 5.00 |
| Revenue From Operations / Share (Rs.) | 944.17 | 857.61 | 813.23 | 658.62 | 483.28 |
| PBDIT / Share (Rs.) | 251.19 | 247.35 | 165.77 | 119.32 | 116.22 |
| PBIT / Share (Rs.) | 232.23 | 232.34 | 150.14 | 104.05 | 101.46 |
| PBT / Share (Rs.) | 231.40 | 231.62 | 162.89 | 115.26 | 101.18 |
| Net Profit / Share (Rs.) | 176.05 | 173.18 | 123.34 | 84.36 | 77.91 |
| PBDIT Margin (%) | 26.60 | 28.84 | 20.38 | 18.11 | 24.04 |
| PBIT Margin (%) | 24.59 | 27.09 | 18.46 | 15.79 | 20.99 |
| PBT Margin (%) | 24.50 | 27.00 | 20.02 | 17.50 | 20.93 |
| Net Profit Margin (%) | 18.64 | 20.19 | 15.16 | 12.80 | 16.12 |
| Return on Networth / Equity (%) | 16.09 | 18.75 | 16.33 | 13.25 | 13.98 |
| Return on Capital Employeed (%) | 20.63 | 24.34 | 19.24 | 15.79 | 17.63 |
| Return On Assets (%) | 13.74 | 15.59 | 13.62 | 10.81 | 11.51 |
| Asset Turnover Ratio (%) | 0.78 | 0.85 | 0.96 | 0.90 | 0.77 |
| Current Ratio (X) | 6.26 | 6.12 | 5.92 | 4.75 | 4.65 |
| Quick Ratio (X) | 5.49 | 5.53 | 5.11 | 3.87 | 3.99 |
| Inventory Turnover Ratio (X) | 5.53 | 5.40 | 5.21 | 5.25 | 4.18 |
| Dividend Payout Ratio (NP) (%) | 2.84 | 2.88 | 4.05 | 5.92 | 6.41 |
| Dividend Payout Ratio (CP) (%) | 2.56 | 2.65 | 3.59 | 5.01 | 5.39 |
| Earning Retention Ratio (%) | 97.16 | 97.12 | 95.95 | 94.08 | 93.59 |
| Cash Earning Retention Ratio (%) | 97.44 | 97.35 | 96.41 | 94.99 | 94.61 |
| Interest Coverage Ratio (X) | 302.41 | 343.36 | 212.79 | 379.45 | 422.05 |
| Interest Coverage Ratio (Post Tax) (X) | 212.94 | 241.41 | 141.97 | 232.60 | 283.93 |
| Enterprise Value (Cr.) | 9977.38 | 6676.60 | 3404.85 | 2895.59 | 2157.70 |
| EV / Net Operating Revenue (X) | 13.33 | 9.82 | 5.28 | 5.55 | 5.63 |
| EV / EBITDA (X) | 50.10 | 34.05 | 25.91 | 30.61 | 23.42 |
| MarketCap / Net Operating Revenue (X) | 13.53 | 9.90 | 5.35 | 5.58 | 5.70 |
| Retention Ratios (%) | 97.15 | 97.11 | 95.94 | 94.07 | 93.58 |
| Price / BV (X) | 11.68 | 9.20 | 5.76 | 5.77 | 4.95 |
| Price / Net Operating Revenue (X) | 13.53 | 9.90 | 5.35 | 5.58 | 5.70 |
| EarningsYield | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Elantas Beck India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Dec 24, the value is 176.05. This value is within the healthy range. It has increased from 173.18 (Dec 23) to 176.05, marking an increase of 2.87.
- For Diluted EPS (Rs.), as of Dec 24, the value is 176.05. This value is within the healthy range. It has increased from 173.18 (Dec 23) to 176.05, marking an increase of 2.87.
- For Cash EPS (Rs.), as of Dec 24, the value is 195.01. This value is within the healthy range. It has increased from 188.19 (Dec 23) to 195.01, marking an increase of 6.82.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 1,093.78. It has increased from 923.34 (Dec 23) to 1,093.78, marking an increase of 170.44.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 1,093.78. It has increased from 923.34 (Dec 23) to 1,093.78, marking an increase of 170.44.
- For Dividend / Share (Rs.), as of Dec 24, the value is 7.50. This value exceeds the healthy maximum of 3. It has increased from 5.00 (Dec 23) to 7.50, marking an increase of 2.50.
- For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 944.17. It has increased from 857.61 (Dec 23) to 944.17, marking an increase of 86.56.
- For PBDIT / Share (Rs.), as of Dec 24, the value is 251.19. This value is within the healthy range. It has increased from 247.35 (Dec 23) to 251.19, marking an increase of 3.84.
- For PBIT / Share (Rs.), as of Dec 24, the value is 232.23. This value is within the healthy range. It has decreased from 232.34 (Dec 23) to 232.23, marking a decrease of 0.11.
- For PBT / Share (Rs.), as of Dec 24, the value is 231.40. This value is within the healthy range. It has decreased from 231.62 (Dec 23) to 231.40, marking a decrease of 0.22.
- For Net Profit / Share (Rs.), as of Dec 24, the value is 176.05. This value is within the healthy range. It has increased from 173.18 (Dec 23) to 176.05, marking an increase of 2.87.
- For PBDIT Margin (%), as of Dec 24, the value is 26.60. This value is within the healthy range. It has decreased from 28.84 (Dec 23) to 26.60, marking a decrease of 2.24.
- For PBIT Margin (%), as of Dec 24, the value is 24.59. This value exceeds the healthy maximum of 20. It has decreased from 27.09 (Dec 23) to 24.59, marking a decrease of 2.50.
- For PBT Margin (%), as of Dec 24, the value is 24.50. This value is within the healthy range. It has decreased from 27.00 (Dec 23) to 24.50, marking a decrease of 2.50.
- For Net Profit Margin (%), as of Dec 24, the value is 18.64. This value exceeds the healthy maximum of 10. It has decreased from 20.19 (Dec 23) to 18.64, marking a decrease of 1.55.
- For Return on Networth / Equity (%), as of Dec 24, the value is 16.09. This value is within the healthy range. It has decreased from 18.75 (Dec 23) to 16.09, marking a decrease of 2.66.
- For Return on Capital Employeed (%), as of Dec 24, the value is 20.63. This value is within the healthy range. It has decreased from 24.34 (Dec 23) to 20.63, marking a decrease of 3.71.
- For Return On Assets (%), as of Dec 24, the value is 13.74. This value is within the healthy range. It has decreased from 15.59 (Dec 23) to 13.74, marking a decrease of 1.85.
- For Asset Turnover Ratio (%), as of Dec 24, the value is 0.78. It has decreased from 0.85 (Dec 23) to 0.78, marking a decrease of 0.07.
- For Current Ratio (X), as of Dec 24, the value is 6.26. This value exceeds the healthy maximum of 3. It has increased from 6.12 (Dec 23) to 6.26, marking an increase of 0.14.
- For Quick Ratio (X), as of Dec 24, the value is 5.49. This value exceeds the healthy maximum of 2. It has decreased from 5.53 (Dec 23) to 5.49, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Dec 24, the value is 5.53. This value is within the healthy range. It has increased from 5.40 (Dec 23) to 5.53, marking an increase of 0.13.
- For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 2.84. This value is below the healthy minimum of 20. It has decreased from 2.88 (Dec 23) to 2.84, marking a decrease of 0.04.
- For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 2.56. This value is below the healthy minimum of 20. It has decreased from 2.65 (Dec 23) to 2.56, marking a decrease of 0.09.
- For Earning Retention Ratio (%), as of Dec 24, the value is 97.16. This value exceeds the healthy maximum of 70. It has increased from 97.12 (Dec 23) to 97.16, marking an increase of 0.04.
- For Cash Earning Retention Ratio (%), as of Dec 24, the value is 97.44. This value exceeds the healthy maximum of 70. It has increased from 97.35 (Dec 23) to 97.44, marking an increase of 0.09.
- For Interest Coverage Ratio (X), as of Dec 24, the value is 302.41. This value is within the healthy range. It has decreased from 343.36 (Dec 23) to 302.41, marking a decrease of 40.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 212.94. This value is within the healthy range. It has decreased from 241.41 (Dec 23) to 212.94, marking a decrease of 28.47.
- For Enterprise Value (Cr.), as of Dec 24, the value is 9,977.38. It has increased from 6,676.60 (Dec 23) to 9,977.38, marking an increase of 3,300.78.
- For EV / Net Operating Revenue (X), as of Dec 24, the value is 13.33. This value exceeds the healthy maximum of 3. It has increased from 9.82 (Dec 23) to 13.33, marking an increase of 3.51.
- For EV / EBITDA (X), as of Dec 24, the value is 50.10. This value exceeds the healthy maximum of 15. It has increased from 34.05 (Dec 23) to 50.10, marking an increase of 16.05.
- For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 13.53. This value exceeds the healthy maximum of 3. It has increased from 9.90 (Dec 23) to 13.53, marking an increase of 3.63.
- For Retention Ratios (%), as of Dec 24, the value is 97.15. This value exceeds the healthy maximum of 70. It has increased from 97.11 (Dec 23) to 97.15, marking an increase of 0.04.
- For Price / BV (X), as of Dec 24, the value is 11.68. This value exceeds the healthy maximum of 3. It has increased from 9.20 (Dec 23) to 11.68, marking an increase of 2.48.
- For Price / Net Operating Revenue (X), as of Dec 24, the value is 13.53. This value exceeds the healthy maximum of 3. It has increased from 9.90 (Dec 23) to 13.53, marking an increase of 3.63.
- For EarningsYield, as of Dec 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Dec 23) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Elantas Beck India Ltd:
- Net Profit Margin: 18.64%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.63% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.09% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 212.94
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 56.4 (Industry average Stock P/E: 340.72)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.64%